DoD Psychological Health and Traumatic Brain Injury Consortium to Alleviate PTSD Award

The summary for the DoD Psychological Health and Traumatic Brain Injury Consortium to Alleviate PTSD Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Psychological Health and Traumatic Brain Injury Consortium to Alleviate PTSD Award: The primary purpose of the collaborative DoD/VA Consortium will be to improve the health and well-being of Service Members (Active Duty, National Guard, and Reservist) and Veterans, with the most effective diagnostics, prognostics, novel treatments, and rehabilitative strategies to treat acute PTSD and to prevent chronic PTSD. This Consortium is responsive to the findings of the recently released DoD/VA-sponsored Institute of Medicine report focused on "Treatment for Posttraumatic Stress Disorder in Military and Veteran Populations". Key priorities of this Consortium are elucidation of factors that influence the different trajectories (onset/progression/duration) of PTSD and associated chronic mental and physical sequelae (including depression, anger/aggression, and substance use/abuse, etc.) and identification of measures for determining who is likely to go on to develop chronic PTSD. The Consortium will therefore work to improve prognostics, advance treatments, and mitigate negative long-term consequences associated with traumatic exposure. Focused scientific efforts to understand and treat PTSD have been supported by the DoD and VA extensively. However, to date, treatments have not been fully successful in all individuals. There remains a significant number who do not respond to the currently available treatment regimens, and the question of predicting treatment response remains a priority.